A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies

References

• Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, . Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007; 60:589–600.
   PubMed Web of Science ®Google Scholar
• Obermayr F. Synergistic in vitro anticancer activity with sequential schedules of JM-118, a metabolite of satraplatin, in combination with erlotinib, paclitaxel, or 5-FU. In AACR-NCI-EORTC Conference; 2005 Poster no. A216.
   Google Scholar
• McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, . Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15:2691–700.
   PubMed Web of Science ®Google Scholar
• Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999;17:3822–7.
   PubMed Web of Science ®Google Scholar
• Kucuk O, Pandya KJ, Skeel RT, Hochster H, Abeloff MD. Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: An Eastern Cooperative Oncology Group study (PA 185). Breast Cancer Res Treat 1999;57:201–6.
   PubMed Web of Science ®Google Scholar
• Pivot X, Chamorey E, Guardiola E, Magné N, Thyss A, Otto J, . Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 2003;14:1578–86.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Guppy AE, Rustin GJ. CA125 response: Can it replace the traditional response criteria in ovarian cancer? Oncologist 2002;7:437–43.
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26: 1148–59.
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, . A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995;36: 451–8.
   PubMed Web of Science ®Google Scholar
• Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res 2003;23:2757–65.
   PubMed Web of Science ®Google Scholar
• Beale P, Raynaud F, Hanwell J, Berry C, Moore S, Odell D, . Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998;42:142–8.
   PubMed Web of Science ®Google Scholar
• Sessa C, Minoia C, Ronchi A, Zucchetti M, Bauer J, Borner M, . Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998;9:1315–22.
   PubMed Web of Science ®Google Scholar
• DeMario MD, Ratain MJ, Vogelzang NJ, Mani S, Vokes EE, Fleming GF, . A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol 1999;43:385–8.
   PubMed Web of Science ®Google Scholar
• Jones S, Hainsworth J, Burris HA 3rd, Thompson D, Raefsky E, Johnson V, . Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies. Invest New Drugs 2002;20: 55–61.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, . Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68: 2–9. Epub 2005 Feb 28.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, . Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009;27:5431–8. Epub 2009 Oct 5.
   PubMed Web of Science ®Google Scholar